Kornimate/medical-research-clean huggingface dataset:
treatments for benign paroxysmal positional vertigo (bppv)

Conditions: Vertigo

Summary: the purpose of this study was to determine the relative short- and long-term efficacy of several physical treatment paradigms commonly employed for the treatment of benign paroxysmal positional vertigo (bppv), including the canalith repositioning (epley) maneuver, the liberatory (semont) maneuver, the brandt-daroff exercises and nonspecific vestibular habituation exercises. these procedures involve exercises and head manipulations. vertigo intensity and frequency, the presence/absence of slow-phase eye movements, the degree of dizziness handicap and acts of daily living (adl) were assessed. the study also ascertained the effects of co-morbid conditions on the response to treatment. while bppv is a common and significant public health problem that has been recognized for several decades, this is the first systematic study of the relative treatment efficacy of different physical treatment modalities for this disorder.


Eligibility criteria:
inclusion criteria: patients may be eligible for this study if they: * are at least 21 years old. * have a diagnosis of unilateral posterior semicircular canal bppv according to established clinical test criteria. * have functional to normal range of motion of the neck and the back. exclusion criteria: patients will not be eligible for this study if they: * have a history of prior ear surgery or prior treatment for bppv. * have an orthopedic or connective tissue disorder that impairs functional neck or trunk range of motion. * have a significant neurological disorder or spinal cord damage. * are on vestibular suppressant medications. * have meniere's disease or acoustic neuromas.

Keywords: physical therapy vertigo rehabilitation occupational therapy
lymphocyte to procalcitonin ratio in covid-19 patients

Conditions: COVID-19

Summary: the lymphocyte/crp ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. in this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on ct, need for mechanical ventilation, mortality and survival is aimed to be determined. the lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.

the lymphocyte/crp ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. in this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on ct, need for mechanical ventilation, mortality and survival is aimed to be determined. the lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age. the auc value, ppv and specificity of the lymphocyte/procalcitonin ratio were higher than the lymphocyte/crp ratio.

Eligibility criteria:
inclusion criteria: * covid19 pcr test positive exclusion criteria: * pregnancy under 18 years old
cbt-i for sleep, pain, and inflammation in crohn's disease

Conditions: Crohn Disease; Insomnia; Sleep Disturbance; Pain; Inflammation

Summary: people with crohn's disease often suffer from sleep problems. long term, sleep problems may lead to more flares of crohn's disease or other complications. in general, people with crohn's disease also report that sleep problems can worsen symptoms of crohn's disease the next day. in people with other medical problems, research has also shown that having sleep problems can make other things worse, such as pain and inflammation. in this study, the researchers want to understand the treatment of sleep problems in people with crohn's disease, and what else might improve if sleep gets better. this study will use cognitive behavioral therapy for insomnia (cbt-i) to treat insomnia symptoms. cbt-i is the recommended treatment for insomnia and has been shown to improve sleep problems, pain, and inflammation in other groups of people. if this study is successful, it will contribute to understanding how to treat insomnia in people with crohn's disease and how sleep impacts pain and inflammation. long term, this information will be helpful in understanding how best to take care of people with crohn's disease.


Eligibility criteria:
inclusion criteria: * mild to moderate crohn's disease (as assessed by pro-3 score) * insomnia severity index score of 8 or greater * sleep onset latency and/or wake after sleep onset of at least 30 minutes * access to device and internet/cell phone service sufficient for telehealth exclusion criteria: * phq-9 score of 20 or greater * gad-7 score of 20 or greater * unstable major psychiatric condition * current alcohol or substance abuse * current narcotic use for pain control * current systemic corticosteroid use * current pregnancy or nursing * ileostomy or colostomy * diagnosis of seizure disorder * diagnosis of sleep apnea or positive stop-bang screen * diagnosis of restless leg syndrome or positive cambridge-hopkins rlsq screen * night shift, rotating shift work, or frequent travel outside of primary time zone
differential metabolic effects of statins

Conditions: Hypercholesterolemia

Summary: the investigators hypothesized simvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.


Eligibility criteria:
inclusion criteria: * low-density lipoprotein cholesterol levels \> 130 exclusion criteria: * overt liver disease, * chronic renal failure * hypothyroidism * myopathy * uncontrolled diabetes * severe hypertension

Keywords: lipophilic statins insulin resistance simvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.
functional trunk training in ataxia patients

Conditions: Ataxia, Spinocerebellar; Ataxias, Hereditary

Summary: the study is to examine the effect of functional trunk training on trunk control and upper extremity functions in patients with autosomal recessive ataxia.

hereditary ataxias are a group of genetic diseases characterized by slow progressive gait disturbance. in addition, coordination disorders can be seen in extremities, speech and eye movements. atrophy is common in the cerebellum. friedreich's ataxia, ataxia telangiectasia, ataxia with vitamin e deficiency, infantile-onset spinocerebellar atrophy and marinesco-sjögren syndrome are autosomal recessive hereditary ataxias. the constant main sign of autosomal recessive ataxia is progressive ataxia. the trunk has an important role on dynamic stabilization for postural reactions and limb movements. a good trunk support enables movements in other parts of the body to occur more regularly. trunk stabilization is important to support upper and lower extremity movements, to meet the loads, and to protect the spinal cord. the relationship between upper extremity function, daily living activities and trunk functions has been emphasized in many studies but comparative studies about the rehabilitation were very less. this study is to evaluate the effect o functional trunk training in patients with autosomal recessive ataxia.

Eligibility criteria:
inclusion criteria: * without any communication impairment (seeing, hearing, hearing), * have not had surgery for the upper and lower extremities in the last 6 months, * between the ages of 5 and 18, * the mental level determined by the pediatrician is sufficient, exclusion criteria: * patients who want to leave the study at any stage of the study * patients who do not attend regular training

Keywords: ataxia,rehabilitation,trunk,disabilities
periodontal and cardiovascular diseases project

Conditions: Periodontitis; Cardiovascular Diseases

Summary: the purpose of this study is to investigate whether basic periodontal therapy aim to reduce subgingival levels of porphyromonas gingivalis and aggregatibacter actinomycetemcomitans, has an impact on the vascular function of patients suffering from established cardiovascular disease.

design: randomized clinical trial, parallel design, double blinded. sample: 120 patients from the cardiology department of hospital severo ochoa (leganés, madrid) suffering from established cardiovascular disease and generalized moderate/severe periodontitis. sixty patients will be randomized to test group (scaling and root planing + systemic antimicrobials), and the other 60 subjects will be included in the control group, consisting on delayed periodontal treatment (supragingival prophylaxis + placebo). study visits: visit 1: screening visit 2: baseline data collection (medical history, clinical variables, gingival crevicular fluid (gcf) samples, vascular function) visit 3: panoramic x-ray, blood samples, randomization and first treatment session. visit 4: second treatment session. visit 5: 24 hours inflammatory biomarkers assessment. visit 6: 7 days inflammatory biomarkers assessment. visit 7: 1 month follow up (clinical variables) visit 8: 3 months follow up (clinical variables, vascular function) and supportive periodontal therapy. visit 9: 6 months follow up (clinical variables, gcf samples, inflammatory biomarkers, vascular function) and supportive periodontal therapy.

Eligibility criteria:
inclusion criteria: * (1) patients with established cardiovascular disease (unstable angina or stroke in the previous 3 to 12 months, and left ventricular ejection fraction ≥50%); * (2) diagnosis of moderate to severe generalized periodontitis (pd\>5mm and marginal bone loss \>30% on at least 50% of the teeth, according to tonetti et al. 2007); * (3) presence of at least 3 teeth per quadrant. exclusion criteria: * (1) periodontal treatment in the previous year; * (2) antibiotic intake in the previous 3 months; * (3) smokers of ≥10 cigarettes per day; * (4) pregnancy or breast feeding; * (5) diabetes mellitus types i or ii, with glycosylated hemoglobin values \>7; * (6) necrotizing periodontal diseases; * (7) hiv infection; * (8) chronic intake of nsaid

Keywords: periodontitis cardiovascular diseases bacteremia scaling and root planing flow-mediated dilation carotid intima-media thickness porphyromonas gingivalis aggregatibacter actinomycetemcomitans
a one year clinical trial assessing the usefulness and safety of inhaled insulin in diabetics with asthma

Conditions: Asthma; Diabetes Mellitus

Summary: a one year clinical trial assessing the usefulness and safety of inhaled insulin in diabetics with asthma


Eligibility criteria:
inclusion criteria: * diabetes mellitus (type 1 or type 2) currently controlled with injected insulin * mild intermittent or mild to moderate persistent asthma exclusion criteria: * poorly controlled, unstable or steroid-dependent asthma, insulin pump therapy, smoking
continuous serrates plane block in axillary dissection

Conditions: Breast Cancer

Summary: patients undergone to axillary dissection during breast surgery with a pecs i, ii block will be randomized to receive either a serratus plane continuous local anesthetic infusion through a multiple hole catheter or nothing. both groups will receive a patient controlled analgesia with morphine.

84 patients asa i-iii undergoing breast surgery with axillary dissection after modified pecs ii block as described by blanco et al. with ropivacaine 0.37% 30 ml. general anesthesia with remifentanil 0.1 mcg/kg/min and propofol 1.5-2 mg/kg to facilitate endotracheal intubation will provide for all patients, and maintained with desflurane and remifentanil infusion. in case of axillary dissection patient will be randomized to receive either a serratus plane continuous local anesthetic infusion through a multiple hole catheter or nothing. both groups will receive as intraoperative analgesia 1 g acetaminophene ev 30 minute before the end of the surgery and 1g. 8h-1 postoperative associated to a patient controlled analgesia with morphine. pca will set up as follow: bolus 1 mg, lock-out 6 minute, max 20 mg/4h. in the serratus group 10 ml of ropivacaine 0.5% before fascial closure and a continuous infusion of 12 ml/h of ropivacaine 0.2% will be provide.

Eligibility criteria:
inclusion criteria: * age \> 18 * breast surgery * informed consent exclusion criteria: * asa \>3 * allergy to local anesthetic * opioid administration in the last month * patient refusal

Keywords: regional anesthesia
study to assess the clinical efficacy and safety of intravitreal aflibercept injection (iai;eylea®;bay86-5321) in patients with branch retinal vein occlusion (brvo)

Conditions: Branch Retinal Vein Occlusion

Summary: this is a phase iii, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of intravitreal aflibercept injection (iai;eylea®;bay86-5321) compared to laser treatment in patients with macular edema secondary to brvo.


Eligibility criteria:
inclusion criteria: the following inclusion criteria include, but are not limited to: 1. adults ≥ 18 years of age with foveal center-involved macular edema (me) secondary to brvo diagnosed within 12 months before the screening visit 2. etdrs bcva: letter score of 73 to 24 (20/40 to 20/320) in the study eye at screening and at day 1 3. provide signed informed consent exclusion criteria: the following exclusion criteria include, but are not limited to: 1. current bilateral manifestation of brvo 2. uncontrolled glaucoma defined as ≥ 25 mmhg on optimal medical regimen, or previous filtration surgery in either the study eye or the fellow eye 3. insufficient clearing of macular hemorrhage that would prevent the patient from receiving laser treatment safely on day 1 (patients that meet this criterion may be rescreened once the macular hemorrhage resolves) 4. uncontrolled diabetes mellitus (dm) 5. previous use of intraocular corticosteroids or anti-angiogenic drugs in the study eye 6. use of periocular corticosteroids in the study eye within 3 months before day 1 7. use of intraocular or periocular corticosteroids or anti-angiogenic drugs in the fellow eye within 3 months before day 1 8. previous administration of systemic anti-angiogenic medications 9. panretinal scatter photocoagulation, sector laser photocoagulation, or macular grid photocoagulation in the study eye
dyslipidemia study investigating the increase in "good cholesterol"

Conditions: Dyslipidaemias

Summary: an eight week comparison of the investigational drug gw590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low levels of good cholesterol and high levels of bad cholesterol.

a multi-center, three-staged, randomized, parallel group, sequential, double-blind, fenofibrate-and placebo-controlled dose-response evaluation of the safety, tolerability, and effects on plasma hdlc and tg of eight weeks treatment with 1µg to 20µg daily doses of gw590735 in otherwise healthy subjects with low hdlc, mildly to moderately elevated tg, and normal ldlc

Eligibility criteria:
inclusion criteria: * high-density lipoprotein cholesterol less than or equal to 45 mg/dl. * triglycerides greater than or equal to 120 mg/dl and less than or equal to 500 mg/dl. * women must be surgically sterile or postmenopausal. exclusion criteria: * heart disease * diabetes

Keywords: triglycerides hypertriglyceridemia cholesterol ldl hdl
insights into participating in studies for bone cancer

Conditions: Bone Cancer

Summary: clinical studies, with a distinct focus on bone cancer, play a crucial role in evaluating the safety and effectiveness of novel treatments for this disease. these trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. the primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * diagnosis of bone cancer * no prior treatment for bone cancer exclusion criteria: * has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * enrolled in another research study * inability to provide written informed consent

Keywords: bone cancer
x-82 to treat age-related macular degeneration

Conditions: Age-Related Macular Degeneration (AMD); Macular Degeneration; Exudative Age-related Macular Degeneration; AMD; Macular Degeneration, Age-related, 10; Eye Diseases; Retinal Degeneration; Retinal Diseases

Summary: the purpose of this study is to evaluate the safety and efficacy of x-82 in the treatment of vision loss due to wet amd.

subjects will be randomized in a 1:1:1:1 ratio to the following dose groups: * x-82 50 mg plus ivt anti-vegf prn * x-82 100 mg plus ivt anti-vegf prn * x-82 200 mg plus ivt anti-vegf prn * placebo plus ivt anti-vegf prn subjects will be treated for a total of 52 weeks with one of three doses of x-82 or placebo. primary efficacy outcome: the primary efficacy outcome is the change in visual acuity score from day -1 to 52 weeks after randomization. safety outcomes: systemic and ocular safety will be evaluate by assessing ecg, laboratory analyses, adverse events and serious adverse events. approximately 132 subjects will be randomized into one of the four arms (33 subjects per dose group).

Eligibility criteria:
inclusion criteria: * participants mush have wet amd which has been diagnosed and treated with anti-vegf in one or both eyes for at least 6 months prior to joining the study and has required at least two prior injections of intravitreal (ivt) anti-vegf at intervals of not greater than 6 weeks for the past two injections in the eye that is selected to be the study eye. * must have demonstrated a reduction in macular fluid or macular thickness in the study eye 14 days following an anti-vegf injection at screening visit 1 * early treatment diabetic retinopathy (etdrs) best corrected visual acuity (bcva) of 25 letters (20/320) or better in both eyes exclusion criteria: * previous vitrectomy to the study eye within 30 days of screening visit 1 * choroidal neovascularization (cnv) due to causes other than amd * proliferative diabetic retinopathy in either eye

Keywords: vascular endothelial growth factor (vegf) platelet derived growth factor (pdgf) amd
pleural effusion biomarkers in lung adenocarcinoma patients

Conditions: Biomarkers; Lung Adenocarcinoma; Pleural Effusion

Summary: this project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as potential diagnostic genes for lung adenocarcinoma.

background： pleural effusion is characterized by abnormal fluid accumulation within the pleural cavity. patients with pleural effusion commonly present with symptoms such as thoracic tightness, dyspnea, cough, and thoracic pain. the etiology of pleural effusion is multifactorial, encompassing conditions such as tuberculosis infection, heart failure, autoimmune disorders, and malignancies. when cancer cells invade the pleural space, malignant pleural effusion occurs. common primary sites of pleural effusion include the lungs, breasts, ovaries, and gastrointestinal tract. hence, precise diagnosis and etiological determination are imperative for guiding therapeutic interventions and optimizing patient outcomes. although the diagnosis of malignant pleural effusion predominantly relies on biomarkers, there remains scope for enhancing the sensitivity and specificity of traditional biomarkers. study design： this study is a two-year, single-center, prospective case-control research methods： the study plans to collect 100 cases of malignant and non-malignant pleural effusion samples from clinical patients. the molecular marker analysis will be performed on the supernatant and sedimented cells obtained through centrifugation. the investigator will compare the expression levels of marker genes previously identified in lung cancer cell models between malignant and non-malignant pleural effusion samples. the concentration of secretory proteins in the supernatant of pleural effusion will be analyzed using immunoblot assay, and the intracellular proteins will be analyzed using immunohistochemical staining. effect： based on the experimental results, the investigator aim to identify novel diagnostic molecules for malignant pleural effusion and combine them with other diagnostic markers to enhance the sensitivity and specificity of clinical diagnosis.

Eligibility criteria:
inclusion criteria: * patients requiring thoracentesis for pleural effusion drainage as determined by a physician based on clinical need. * signed informed consent. exclusion criteria: * patients under the age of 18. * patients with malignancies other than lung adenocarcinoma.

Keywords: pleural effusion biomarkers lung cancer clinical diagnosis
the explore mg registry for myasthenia gravis

Conditions: Myasthenia Gravis

Summary: the purpose of this study is to create a yale university department of neurology myasthenia gravis (mg) registry that will be used for current and future research projects involving the study of myasthenia gravis.

this registry will allow for the research of several mechanisms of myasthenia gravis (mg) by studying peripheral blood, stool, disease status and course, and treatment of subjects with mg. the explore-mg registry focuses on varied aspects of mg such as disease management, health care utilization, health costs, disease characteristics, and diagnostic tools. as such, it will aid in a broader understanding of mg, while providing a registry from which questions about the disease may be better answered.

Eligibility criteria:
inclusion criteria: * adult patients diagnosed with myasthenia gravis presenting to the yale department of neurology for clinical care or research interventions will be invited to donate their biological specimens/clinical data. exclusion criteria: * failure to meet the inclusion criteria.
partial zona pellucida removal by assisted hatching of blastocysts

Conditions: Infertility

Summary: the aim of study is to assess the possible impact of assisted hatching on delivery rate after transfer of vitrified-warmed human blastocysts.

zona pellucida (zp) manipulation, termed "assisted hatching" (ah), has been introduced in order to favor embryo hatching and ultimately improve assisted reproductive technology success but with poor proofs of safety and biological plausibility. vitrifying and warming of blastocysts may impair the successful hatching process of the embryo out of its zp and its following implantation into the uterus. theoretically, ah may facilitate the hatching process and subsequently increase implantation rates. in this prospective randomized controlled trial (rct), the hypothesis is to test whether the application of a partial ah to vitrified/warmed blastocysts might affect patients' delivery rate. patients with vitrified blastocysts will be randomized at the time of blastocyst warming to a study group (with ah) or a control group (without ah). ah will be performed at the expanded blastocyst stage using a laser technique and a laser opening will be initiated at the 1 o'clock position. consecutive laser shots will be applied to reach the 5 o'clock position of the blastocyst. the blastocysts will then be cultured at least 2 h and subsequently transferred into the patient's uterus.

Eligibility criteria:
inclusion criteria: * single embryo transfer of vitrified/warmed blastocyst (set) * first or second frozen ivf (with or without intracytoplasmic sperm injection) cycle of blastocysts * first or second oocyte retrieval exclusion criteria: * preimplantation genetic testing (pgt) cycle * bmi \> 35 kg/m2 * severe male factor * abnormal uterine cavity

Keywords: assisted hatching zona pellucida implantation failure blastocyst cryopreservation